CN115768788A - Il-2变体 - Google Patents

Il-2变体 Download PDF

Info

Publication number
CN115768788A
CN115768788A CN202180048794.7A CN202180048794A CN115768788A CN 115768788 A CN115768788 A CN 115768788A CN 202180048794 A CN202180048794 A CN 202180048794A CN 115768788 A CN115768788 A CN 115768788A
Authority
CN
China
Prior art keywords
protein
seq
cancer
reduction
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048794.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·S·权
S·H·李
S·W·任
J·K·崔
H·T·孙
J·W·李
H·N·李
S·H·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eutilex GmbH
Original Assignee
Eutilex GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex GmbH filed Critical Eutilex GmbH
Publication of CN115768788A publication Critical patent/CN115768788A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CN202180048794.7A 2020-07-09 2021-07-07 Il-2变体 Pending CN115768788A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050068P 2020-07-09 2020-07-09
US63/050,068 2020-07-09
PCT/IB2021/056106 WO2022009123A1 (en) 2020-07-09 2021-07-07 Il-2 variants

Publications (1)

Publication Number Publication Date
CN115768788A true CN115768788A (zh) 2023-03-07

Family

ID=79552299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048794.7A Pending CN115768788A (zh) 2020-07-09 2021-07-07 Il-2变体

Country Status (6)

Country Link
US (1) US20230242607A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185605A4 (cg-RX-API-DMAC7.html)
JP (1) JP7819944B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230037612A (cg-RX-API-DMAC7.html)
CN (1) CN115768788A (cg-RX-API-DMAC7.html)
WO (1) WO2022009123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
WO2020069398A1 (en) * 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
CN112105633A (zh) * 2018-09-21 2020-12-18 信达生物制药(苏州)有限公司 新型白介素2及其用途
CN112218884A (zh) * 2018-05-07 2021-01-12 免疫分子中心 由白介素-2突变蛋白和i型干扰素构成的融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
CA3117853A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
EP4172216A4 (en) * 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
CN112218884A (zh) * 2018-05-07 2021-01-12 免疫分子中心 由白介素-2突变蛋白和i型干扰素构成的融合蛋白
CN112105633A (zh) * 2018-09-21 2020-12-18 信达生物制药(苏州)有限公司 新型白介素2及其用途
WO2020069398A1 (en) * 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides

Also Published As

Publication number Publication date
JP7819944B2 (ja) 2026-02-25
EP4185605A4 (en) 2024-07-17
WO2022009123A1 (en) 2022-01-13
KR20230037612A (ko) 2023-03-16
JP2023534793A (ja) 2023-08-14
EP4185605A1 (en) 2023-05-31
WO2022009123A4 (en) 2022-02-24
US20230242607A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
Jin et al. Emerging new therapeutic antibody derivatives for cancer treatment
JP7690552B2 (ja) CD137抗原結合部位を含むFc結合断片
BR112020023346A2 (pt) anticorpo capaz de se ligar a muc1 e seu uso, ácido nucleico, cassete ou vetor de expressão, célula hospedeira, conjugado, composição, e, métodos para aumentar a afinidade de ligação a muc1 de um anticorpo e para produzir um anticorpo com afinidade de ligação a muc1 aumentada
CN110366561A (zh) 免疫应答的条件性激动剂
CN112739379A (zh) 包含OX40抗原结合位点的Fc结合片段
WO2023006082A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
EP3980452A1 (en) Recombinant 4-1bb binding proteins and their use
EP4159759A1 (en) Anti-b7-h3 antibody and preparation therefor and use thereof
JP7819944B2 (ja) Il-2バリアント
JP2025098135A (ja) Pd-1ポリペプチド変異体
WO2023036270A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2025517405A (ja) Neo-201抗体を使用した骨髄由来抑制細胞を除去するための方法
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
KR20230085904A (ko) 암을 치료하기 위한 방법 및 조성물에 사용하기 위한 초항원 접합체
CN119301159A (zh) 重组tim-4蛋白、嵌合抗原受体(car)t细胞递送系统及其制备方法和使用方法
KR20220155589A (ko) Il-18을 분비하는 gpc3 car-t 세포 및 이의 제조 및 사용 방법
JP2020508636A (ja) IFN−γ誘導性制御性T細胞転換性抗癌(IRTCA)抗体およびその使用
WO2023169583A1 (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
WO2023133842A1 (zh) 一种靶向IL-18Rβ的抗体及其应用
HK40121113A (en) Methods for ablating myeloid derived suppressor cells using neo-201 antibody
HK40103619A (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
CA2930243C (en) Epha3 and multi-valent targeting of tumors
CN121127259A (zh) 用于结合功能障碍的p2x7受体的嵌合抗原受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination